Your browser doesn't support javascript.
loading
ELISA with recombinant antigen Lb6H validated for the diagnosis of American tegumentary leishmaniasis.
Valencia-Portillo, Ruth Tamara; Lindoso, José Angelo; Celeste, Beatriz Julieta; Bittencourt, Amanda Azevedo; de Brito, Maria Edileuza Felinto; Duthie, Malcolm Scott; Guderian, Jeffery; Guerra, Jorge; Oliveira, Ana Lúcia Lyrio; Reed, Steven; Rocha, Mussya Cisotto; Santos, Nicolle Tayná; Silveira, Fernando Tobias; Goto, Hiro; Sanchez, Maria Carmen Arroyo.
Affiliation
  • Valencia-Portillo RT; Faculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
  • Lindoso JA; Faculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
  • Celeste BJ; Instituto de Infectologia Emílio Ribas, Secretaria de Saúde do Estado de Sao Paulo, Sao Paulo, São Paulo, Brazil.
  • Bittencourt AA; Faculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Protozoologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
  • de Brito MEF; Faculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
  • Duthie MS; Faculdade de Medicina, Departamento de Medicina Preventiva, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
  • Guderian J; Instituto de Infectologia Emílio Ribas, Secretaria de Saúde do Estado de Sao Paulo, Sao Paulo, São Paulo, Brazil.
  • Guerra J; Global Medical Affairs, MSD in Brazil, Sao Paulo, São Paulo, Brazil.
  • Oliveira ALL; Centro de Pesquisas Aggeu Magalhães, Fundacao Oswaldo Cruz, Recife, Pernambuco, Brazil.
  • Reed S; Host Directed Therapeutics, Seattle, Washington, United States of America.
  • Rocha MC; Access to Advanced Health Institute, Seattle, Washington, United States of America.
  • Santos NT; Fundacao de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
  • Silveira FT; Faculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
  • Goto H; Host Directed Therapeutics, Seattle, Washington, United States of America.
  • Sanchez MCA; Laboratório de Investigação Médica (LIM 48), Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
PLoS One ; 19(6): e0304268, 2024.
Article in En | MEDLINE | ID: mdl-38838004
ABSTRACT
American tegumentary leishmaniasis (ATL) diagnosis is an open question, and the search for a solution is urgent. The available tests that detect the etiological agent of the infection are specific for ATL diagnosis. However, they present disadvantages, such as low sensitivity and the need for invasive procedures to obtain the samples. Immunological methods (leishmanin skin test and search for anti-Leishmania antibodies) are good alternatives to the etiological diagnosis of ATL. Presently, we face problems with disease confirmation due to the discontinuity in the production of leishmanin skin test antigen, particularly in resource-poor settings. Aiming to diagnose ATL, we validated rLb6H-ELISA for IgG antibodies using 1,091 samples from leishmaniasis patients and healthy controls, divided into four panels, living in 19 Brazilian endemic and non-endemic states. The rLb6H-ELISA showed a sensitivity of 98.6% and a specificity of 100.0%, with the reference panel comprising 70 ATL patient samples and 70 healthy controls. The reproducibility evaluation showed a coefficient of variation of positive samples ≤ 8.20% for repeatability, ≤ 17,97% for reproducibility, and ≤ 8.12% for homogeneity. The plates sensitized with rLb6H were stable at 4°C and -20°C for 180 days and 37°C for seven days, indicating 12 months of validity. In samples of ATL patients from five research and healthcare centers in endemic and non-endemic areas, rLb6H-ELISA showed a sensitivity of 84.0%; no significant statistical difference was observed among the five centers (chi-square test, p = 0.13). In samples of healthy controls from four areas with different endemicity, a specificity of 92.4% was obtained; lower specificity was obtained in a visceral leishmaniasis high endemicity locality (chi-square test, p<0.001). Cross-reactivity was assessed in 166 other disease samples with a positivity of 13.9%. Based on the good diagnostic performance and the reproducibility and stability of the antigen, we suggest using ELISA-rLb6H to diagnose ATL.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / Leishmaniasis, Cutaneous / Antigens, Protozoan Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Country/Region as subject: America do sul / Brasil Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Enzyme-Linked Immunosorbent Assay / Leishmaniasis, Cutaneous / Antigens, Protozoan Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Country/Region as subject: America do sul / Brasil Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2024 Document type: Article Affiliation country:
...